


| Key | % Net Assets |
|---|---|
| 6.2% | |
| 5.0% | |
| 4.6% | |
| 4.2% | |
| 80% |
| Name | % Net Assets |
|---|---|
| GlaxoSmithKline | 6.2% |
| BP | 5.0% |
| Royal Dutch Shell | 4.6% |
| UBM | 4.2% |
| Tyman plc | 4.1% |
| Henry Boot | 3.9% |
| Goals | 3.7% |
| Balfour Beatty | 3.1% |
| Reed Elsevier | 3.0% |
| Hays | 3.0% |
| Key | % Net Assets |
|---|---|
| 21.20% | |
| 20.00% | |
| 19.90% | |
| 11.30% | |
| 11.00% |
| Date | 13-Apr-2017 |
|---|---|
| NAV | 123.23p |
| Currency | GBP |
| Change | 0.000p |
| % | n/a |
| YTD change | 123.23p |
| YTD % | n/a |
| Fund Inception | 14/05/2004 |
|---|---|
| Fund Manager | Matthew Tillet |
| TER | 1.15 (31-Jan-2014) |
| Minimum Investment | |
|---|---|
| Initial | n/a |
| Additional | n/a |
| Savings | n/a |
| Charges | |
|---|---|
| Initial | n/a |
| Annual Mang't | 0.75% |
| Exit | n/a |
| Name | % |
|---|---|
| No risk data available. | |
You are here: research